
REFERENCES

- **ACE Inhibitor MI Collaborative Group.** Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. *Circulation* 1998; 97:2202—12.
- **Ackerman M J.** The long QT syndrome: ion channel diseases of the heart. *Mayo Clin Proc* 1998; 73:250-69.
- **Adams J E, Bodor GS, Davila-Roman V G, et al.** Cardiac troponin I: a marker with high specificity for cardiac injury. *Circulation* 1993; 88:101-6.
- **Akhobadze T T, Chumburidze V B, Kurashvili R B, et al.** *American J.Hypertension* 2001, 14 (Supplement 1): A246
- **Ali Moustapha, H. Vernon Anderson,** Contemporary View of the Acute Coronary Syndromes. *J Invasive Cardiol* 2003; 15(2):71-79.
- **Alpert J S, Thygesen K, Antman E, et al.** Myocardial infarction redefined— A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol.* 2000 36:959.
- **Anderson K M, Wilson P W F, Odell P M, et al.** An updated coronary risk profile: A statement for health professionals. *Circulation*, 1991; 83, 356-362.
- **Antman EM.** Decision making with cardiac troponin tests. *N Engl J Med* 2002; 346:2079.

-
- **Antman E M, Anbe D T, Armstrong P W, et al.** ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *Circulation* 2004; 110:588.
 - **Antman E M, Morrow D A, McCabe C H, et al.** Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Engl J Med* 2006; 354:1477-88.
 - **Antman E M, Tanasijevic M J, Thompson B, et al.** Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. *N Engl J Med.* 1996; 335:1342-1349.
 - **Antzelevitch C, Shimizu W, Yan G X, et al.** Cellular basis for QT dispersion. *J Electrocardiol* 1998; 30:168–173.
 - **Antzelevitch C, Sicouri S.** Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: role of M cells in the generation of U waves, triggered activity and torsade de pointes. *J Am Coll Cardiol.* 1994; 23:259–277.
 - **Appel L J, Moore T J, Obarzanek E, et al.** A clinical trial of the effects of dietary patterns on blood pressure. *N. Engl. J. Med* 1997; 336, 1117-1124.
 - **Apple F S, Murakami M M, Jesse R L, et al.** Near-bedside whole-blood cardiac troponin I assay for risk assessment of

patients with acute coronary syndromes. Clin Chem. 2002 48:1784.

- **Arildsen H, May O, Christiansen E H, et al.** Increased QT dispersion in patients with insulin-dependent diabetes mellitus. Int J Cardiol. 1999; 71(3):235-42.
- **Arnltage P & Berry G.** Statistical methods in medical research. Boston, MA: Blackwell Scientific. 1987. 559.
- **Arntz H-R, Bossaert L, Gerasimos S. Filippatos G S,** European Resuscitation Council Guidelines for Resuscitation 2005: Initial management of acute coronary syndromes. Resuscitation (2005) 67S1, S87—S96.
- **Ashikaga T, Nishizaki M, Arita M, et al.** Effect of dipyridamole on QT dispersion in vasospastic angina pectoris. Am J Cardiol 1999; 84: 807–10.
- **Assessment of the Safety and Efficacy of a New Thrombolytic Investigators.** Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999; 354, 716-722.
- **Assmann G, Cullen P, Schulte H.** The MünsterHeart Study (PROCAM) .Results of followup at 8 years. Eur. Heart J., 1998; 19, A2-A11.
- **Aversano T, Aversano L T, Passamani E.** Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA.2002; 287, 1943-1951.

-
- **Baldus S, Heeschen C, Meinertz T, et al.** Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation* 2003; 108: 1440–1445.
 - **Bashore, T M, Bates E R, Berger P B, et al.** ACC/SCAI clinical expert consensus document on cardiac catheterization laboratory standards. *J Am Coll Cardiol.* 2001; 37:2170.
 - **Bassand J P, Hamm C W, Ardissino D, et al.** ECS Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. *European Heart Journal.* 2007; doi:10.1093/eurheartj/ehm161.
 - **Behar S.** Lowering fibrinogen levels clinical update. BIP Study Group. Bezafibrate infarction Prevention. *Blood Coagul. Fibrinolysis*, 1999; 10, 41-43.
 - **Bennemeier H, Hartmann F, Giannitsis E, et al.** Effects of primary angioplasty on the course of QT dispersion after myocardial infarction and its association with infarct size. *PACE* 1999; 22: A 19(abstr).
 - **Bennett C L, Connors J M, Carwile J M, et al.** Thrombotic thrombocytopenic purpura associated with clopidogrel. *N Engl J Med* 2000; 342:1773-7.
 - **Berliner J A, Navab M, Fogelman A M, et al.** Atherosclerosis basic mechanisms: Oxidation, inflammation, and genetics. *Circulation*, 1995; 91, 2488-2496.
 - **Bernardi V, Szarfer J, Summay G, et al.** Long-term versus short-term clopidogrel therapy in patients undergoing coronary

stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). *Am J Cardiol* 2007; 99:349-52.

- **Bertrand M E, Rupprecht H-J, Urban P, et al.** Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 2000; 102:624–629.
- **Bertrand M E, Simoons M L, Fox A A, et al.** Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal* (2002) 23, 1809–1840.
- **Bibbins-Domingo K, Ansari M, Schiller N B.** B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. *Circulation* 2003; 108:2987-2992.
- **Bikkina M, Levy D, Evans J C, et al.** Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. *JAMA*, 1994; 272, 33-36.
- **Bittl JA, Feit F, for Hirulog Angioplasty Study Investigators.** A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for post-infarction angina. *Am J Cardiol* 1998; 82: 43P-9.
- **Boersma E.** Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J*: 2006; 27, 779-788.

-
- **Boersma E, Akkerhuis K M, Theroux P, et al.** Platelet glycoprotein IIb/IIIa receptor inhibition in non–ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. *Circulation* 1999; 100:2045–8.
 - **Boersma E, Harrington R A, Moliterno D J, et al.** Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *Lancet* 2002;359:189—98 [erratum appears in *Lancet* 2002 Jun 15; 359(9323):2120].
 - **Boersma E, Mercado N, Poldermans D, et al.** Acute myocardial infarction. *Lancet*: 2003; 361, 847-858.
 - **Boushey C J, Beresford S A, Omenn G S, et al.** A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA*, 1995; 274, 1049-1057.
 - **Braunwald E, Antman E M, Beasley J W, et al.** ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). *Circulation*. 2000; 102:1193-1209.
 - **Braunwald E, Antman E M, Beasley J W, et al.** ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart

Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [published correction appears in J Am Coll Cardiol 2001; 38: 294-5]. J Am Coll Cardiol 2000; 36:970-1062.

- **Brenner H, Heiss G.** The intraindividual variability of fasting triglyceride - a challenge for further standardization. Eur. Heart J., 1990; 11, 1054-1058.
- **Brunner E, Smith G D, Marmot M, et al.** Childhood social circumstances and psychological and behavioral factors as determinants of plasma fibrinogen. Lancet, 1996; 347, 1008-1013.
- **Burtis C A, Ashwood E R.** Textbook of Clinical Chemistry. Philadelphia: W.B. Saunders Co., 1994:58-69.
- **Camargo C A, Stampfer M J, Glynn R J, et al.** Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation 1997; 95, 577.
- **Cannon C P, Braunwald E, McCabe C H, et al;** Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15):1495-504.
- **Cantin B, Gagnon F, Moorjani S, et al.** Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J. Am. Coll. Cardiol., 1998; 31, 519-525.

-
- **Carbajal E V, Deedwania P.** Treating non-ST-segment elevation ACS. Pros and cons of current strategies. *Postgrad Med.* 2005 Sep; 118(3):23-32.
 - **Cardoso C, Salles G, Bloch K, et al.** Clinical determinants of increased QT dispersion in patients with diabetes mellitus. *Int J Cardiol.* 2001; 79(2-3):253-62.
 - **Chapelle, J.P.:** Myoglobin. *Clin. Chem. News*, 1991 17:22.
 - **Chapelle J P, Albert A, Smeets J P, et al.** Serum myoglobin determinations in the assessment of acute myocardial infarction. *Eur Heart J.* 1982 Apr; 3(2):122–129.
 - **Chobanian AV, Bakris G L, Black H R, et al.** The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report *JAMA* 2003, 21: 2560-2572.
 - **Christensen P K, Gall M A, Major-Pedersen A, et al.** QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. *Scand J. Clin. Lab. Invest.* 2000, 60: 323-332.
 - **Cin V G, Celik M, Ulucan S.** QT dispersion ratio in patients with unstable angina pectoris (a new risk factor?). *Clin Cardiol* 1997; 20:533–535.
 - **Clarke R, Frost C, Collins R, et al.,** Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *Br. Med. J.*, 1997; 314, 112-117.
 - **Collins R, Peto R, MacMahon S, et al.** Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. *Lancet*, 1990; 335, 827.

-
- **Cowan J C, Yusoff K, Moore M, et al.** “Importance of lead selection in QT interval measurement” *Am. J. Cardiol.* 61, 83-87, 1988.
 - **Crouch M A, Limon L, Cassano A T.** Clinical Relevance and Management of Drug-Related QT Interval Prolongation. *Pharmacotherapy* 2003; 23(7):881-908.
 - **Davey P.** A new physiological method for heart rate correction of the QT interval. *Heart*1999; 82:183–6.
 - **Davignon J, Loaksonen R.** Low-density lipoprotein-independent effects of statins. *Curr.Opin. Lipidol.*, 1999; 10, 543-559.
 - **Day C P, McComb J M, Campbell R W.** QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. *Br Heart J*1990; 63:342–4.
 - **Day C P, McComb J M, Matthews J, et al.** Reduction in QT dispersion by sotalol following myocardial infarction. *Eur Heart J*1991; 12:423–7.
 - **De Backer G, Ambrosioni E, Borch-Johnsen K, et al.** European guidelines on cardiovascular disease prevention in clinical practice. *Eur J Cardiovasc Prev Rehabil* 2003; 10(suppl 1):S1-S78.24:1601-10.
 - **De Boer O J, van der Wal A C, Teeling P, et al.** Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? *Cardiovasc Res.* 1999; 41(2):443-449.
 - **De Bruyne M C, Hoes A W, Kors J A, et al.** QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. *Circulation*1998; 97:467–72.

-
- **De Faire U, Ericsson C G, Grip L, et al.** Secondary preventive of lipid-lowering drugs. The bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). *Eur. Heart J.*, 1996; 17 (Suppl), 37-42.
 - **De Lemos J A, Antman E M, Giugliano R P, et al.** Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. *Am Heart J* 2000 140:373.
 - **De Lemos J A, Blazing M A, Wiviott S D, et al; A to Z Investigators.** Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004; 292(11):1307-16.
 - **De Ponti F, Poluzzi E, Cavalli A, et al.** Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes. *Drug Saf* 2002; 25:263-86.
 - **De Zwaan C, Bar FW, Janssen JH, et al.** Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. *Am Heart J* 1989; 117: 657–665.
 - **Devereux R B, Pini R, Aurigemma G P, et al.** Measurement of left ventricular mass:methodology and expertise [Editorial]. *J. Hypertens.*, 1997; 15, 801-809.
 - **Diercks D B, Peacock W F, Hiestand B C, et al.** Frequency and consequences of recording an electrocardiogram 10 min after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). *Am J Cardiol* 2006; 97: 437– 442.

-
- **Dilaveris P, Pantazis A, Gialafos E, et al.** The effects of cigarette smoking on the heterogeneity of ventricular repolarization. *Am. Heart J.*, 2001; 142:833-837.
 - **Doven O, Ozdol C, Sayin T, et al.** QT interval dispersion: non-invasive marker of ischemic injury in patients with unstable angina pectoris? *Jpn. Heart J.* 2000, 41: 597-603.
 - **Downs G R, Clearfield M, Weiss S, et al.** Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS (Air force/Texas Coronary Atherosclerosis Study). *J. Am. Med. Assoc.*, 1998; 279, 1615-1622.
 - **Dzau V J.** Resolved and unresolved issues in the prevention and treatment of coronary artery disease. *Am Heart J* 1991; 121:1244-63.
 - **Eagle K A, Goodman S G, Avezum A, et al.** Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). *Lancet*: 359, 2002; 373-377.
 - **Eikelboom J W, Hirsh J, Weit J L, et al.** Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation* 2002; 105:1650-1655.
 - **Elming H, Holm E, Jun L, et al.** The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. *Eur Heart J* 1998; 19:1391–400.

-
- **Ernst E, Resch K L.** Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann. Intern. Med.*, 1993; 118, 956-963.
 - **Faggiotto A, Ross R, Harker L.** Studies of hypercholesterol -emia in the nonhuman primate. I. Changes that lead to fatty streak formation. *Arteriosclerosis*. 1984; 4(4):323-340.
 - **Falk E, Shah P, Fuster V.** Coronary plaque disruption. *Circulation* 1995; 92: 657–71.
 - **Fareed J, Lewis B E, Callas D D, Hoppensteadt D A.** Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. *Clin Appl Thromb Hemost* 1999; 5(suppl 1):S45-55.
 - **Feldman J A, Fish S S, Beshansky J R, et al.** Acute cardiac ischemia in patients with cocaine-associated complaints: results of a multicenter trial. *Ann Emerg Med* 2000; 36: 469-76.
 - **Folsom A R, Nieto J, McGovern P F, et al.** Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*, 1998; 204-210.
 - **Fourth International Study of Infarct Survival Collaborative Group.** **ISIS-4:** A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. *Lancet* 1995; 345:669-85.
 - **Fox K F, Cowie M R, Wood D A, et al.** Coronary artery disease as the cause of incident heart failure in the population. *Eur Heart J* 2001; 22:228-36.

-
- **Freimark D, Matetzky S, Leor J, et al.** Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. *Am J Cardiol* 2002; 89:381—5.
 - **French J K, Ramanathan K, Stewart J T, et al.** A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. *Am Heart J* 145:508, 2003.
 - **Fu G S, Meissner A, Simon R.** Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. *Eur Heart J.* 1997; 18:281–289.
 - **Gaziano J M, Hennekens C H, O'Donnell C J, et al.,** Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. *Circulation*, 1997; 96, 2520-2525.
 - **Gersh B J, Antman E M.** Selection of the optimal reperfusion strategy for STEMI: does time matter? *Eur Heart J:* 27, 2006; 761-763.
 - **Ghali J K, Liao Y, Cooper R S.** Left ventricular hypertrophy in the elderly. *Am. J. Geriatr.Cardiol.*, 1997; 6, 38-49.
 - **Gibbons R J, Fuster V.** Therapy for Patients with Acute Coronary Syndromes — New Opportunities *n engl j med* 2006; 354;14
 - **Gibson R S, Boden W E, Theroux P, et al.** Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. *N Engl J Med* 1986; 315(7):423-9.
 - **Glancy J M, Garratt C J, de Bono D P.** Dynamics of QT dispersion during myocardial infarction and ischaemia. *Int J Cardiol* 1996; 57: 55–60.

-
- **Glancy J M, Garratt C J, Woods K L, et al.** QT dispersion and mortality after myocardial infarction. *Lancet* 1995; 345:945–949.
 - **Gligic B, Romanovic R, Raden G, et al.** Relation between QT dispersion and reperfusion in acute myocardial infarct. *Vojnosanit Pregl* 2003; 60:19–27.
 - **Gluckman T J, Sachdev M, Schulman S P, et al.** A simplified approach to the management of non–ST-segment elevation acute coronary syndromes. *JAMA* 2005; 293(3):349-57 [Erratum, *JAMA* 2005; 293(14):1728.
 - **Goldberger A L.** Clinical electrocardiography: a simplified approach. 6th ed. St. Louis: Mosby, 1999:81-100.
 - **Goldberger A L.** Clinical Electrocardiography: A Simplified Approach. 6th ed. St Louis, Mosby, 1999: 8.
 - **Goldbourt U, Brunner D, Behar S, et al.** Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention Study. *Eur. Heart J.*, 1998; 19 (Suppl H), 42-47.
 - **Goldstein J A, Demetriou D, Grines C L, et al.** Multiple complex coronary plaques in patients with acute myocardial infarction. *N Engl J Med.* 2000; 343(13):915-922.
 - **Goodacre S, Locker T, Morris F, Campbell S.** How useful are clinical features in the diagnosis of acute, undifferentiated chest pain? *Acad Emerg Med* 2002; 9:203-8.
 - **Gum P A, Kottke-Marchant K, Poggio E D, et al.** Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol* 2001; 88:230- 235.

-
- **Gurfinkel E P, Manos E J, Mejail R I, et al.** Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. *J Am Coll Cardiol* 1995; 26:313—8.
 - **GUSTO IIb Investigators.** A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996; 335:775-82.
 - **Halkin A, Grines C L, Cox D A, et al.** Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *J Am Coll Cardiol* 2004; 43:1780—7.
 - **Hamm C W, Goldmann B U, Heeschen C, et al.** Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. *N Engl J Med*. 1997; 337:1648-1653.
 - **Harb T S, Zareba W, Moss A J, et al.** Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. *Am J Cardiol* 2002; 89: 216-221.
 - **Hass W K, Easton J D, Adams H P, et al.** A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Engl J Med* 1989; 321(8):501-7.
 - **He J, Ogden L, Bazzano L, et al.** Risk factors for congestive heart failure in US men and women. *Arch Intern Med* 2001;161:996-1002
 - **Hebert P R, Moser M, Mayer J, et al.** Recent evidence on drug therapy of mild to moderate hypertension and decreased

incidence of coronary heart disease. *Arch. Intern. Med.*, 1993; 153, 578.

- **Heeschen C, Hamm C W, Laufs U, et al.** Withdrawal of statins increases event rate in patients with acute coronary syndromes. *Circulation* 2002; 105:1446—52.
- **Hennekens C H, Buring J E, Manson J E, et al.** Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N. Engl. J. Med.*, 1996; 334, 1145-1149.
- **Herman M P, Sukhova G K, Libby P, et al.** Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. *Circulation*. 2001; 14 (16): 1899-1904.
- **Higham P D, Furniss S S, Campbell R W.** QT dispersion and components of the QT interval in ischaemia and infarction. *Br Heart J* 1995; 73:32–36.
- **Higham P D, Hilton C J, Aitcheson J D, et al.** Does QT dispersion reflect dispersion of ventricular recovery? (abstr)*Circulation*. 1992; 86(Suppl I):392.
- **Higham P D, Hilton D J, Aitcheson J D.** QT dispersion: A measure of underlying dispersion of ventricular recovery? *Eur Heart J* 1993; 14:86.
- **Hii J T, Wyse D G, Gillis A M, et al.** Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. *Circulation* 1992; 86:1376–1382.
- **Hnatkova K, Malik M, Kautzner J, et al.** Adjustment of QT dispersion assessed from 12 lead electrocardiograms for

different numbers of analysed electrocardiographic leads: comparison of stability of different methods. *Br Heart J* 1994; 72:390–6.

- **Hodges M, Salerno D, Erlinen D.** Bazett's QT correction reviewed: evidence that a linear QT correction for heart rate is better. *J Am Coll Cardiol* 1983; 1:694.
- **Hodis H N, Mack W J, Olan D, et al.** Antioxidant vitamin intake reduces progression of carotid artery intima media thickness. *Circulation*, 1996; 94(Suppl 1), 1508.
- **Hohnloser S H.** Effect of coronary ischemia on QT dispersion. *J. Electrocardiol.* 1999, 32: 199-206.
- **Hohnloser S H, van de Loo A, Arendts W, et al.** QT-dispersion in the surface ECG as a marker of increased electrical instability in patients with acute myocardial infarction. *Z Kardiol* 1993; 82:678– 682.
- **Hokanson J E, and Austin M A.** Plasmalipid triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J. Cardiovasc. Risk*, 1996; 3, 213-219.
- **Husted S E, Kristensen S D, Vissinger H, et al.** Intravenous acetylsalicylic acid—dose-related effects on platelet function and fibrinolysis in healthy males. *Thromb Haemost* 1992; 68:226—9.
- **Ileri M, Yetkin E, Tandogan I, et al.** Effect of habitual smoking on QT interval duration and dispersion. *Am. J. Cardiol.* 2002, 15:249-250.

-
- **Ilkay E, Yavuzkir M, Karaca I, et al.** The effect of ST resolution on QT dispersion after interventional treatment in acute myocardial infarction. *Clin Cardiol* 2004; 27:159–62.
 - **International Joint Efficacy Comparison of Thrombolytics.** Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. *Lancet*: 1995 346; 329-336.
 - **ISIS-4 investigators:** a randomised factorial trial assessing early oral captopril, mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet* 1995; 345:669—85.
 - **Jacobs A K, Antman E M, Ellrodt G.** Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. *Circulation*: 2006 113; 2152-2163.
 - **Janse M J, Wit A L.** Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. *Physiol. Rev.* 1989; 69:1049–1169.
 - **Jeppesen J, Hein H O, Suadicani P, et al.** Triglyceride concentration and ischemic heart disease: an eight year follow-up in the Copenhagen Male Study. *Circulation*, 1998; 97, 1029-1036.
 - **Jordaens L J L M,** The clinical value of QT dispersion: new perspectives on the assessment of cardiac repolarization more than 75 years after Bazett's formula. *Europace* (1999) 1, 73–76.

-
- **Kaftan A H, Kaftan O.** QT intervals and heart rate variability in hypertensive patients: *Jpn. Heart J.* 2000, 41:173-182.
 - **Kagen L J.** Myoglobin methods and diagnostic uses. *CRC Crit. Rev. Clin. Lab. Sci.*, 1978;2:273.
 - **Kannel W B.** Blood pressure as a cardiovascular risk factor: prevention and treatment. *J. Am. Med. Assoc.*, 1996; 275, 1571-1576.
 - **Kannel W B, Wolf P A, Castelli W P, et al.** (1987). Fibrinogen and risk of cardiovascular disease. *JAMA*, 1987; 258, 1183-1186.
 - **Karras D J, Kane D L.** Serum markers in the emergency department diagnosis of acute myocardial infarction. *Emerg Med Clin North Am* 2001; 19:321-37.
 - **Kauhanen J, Kaplan G A, Goldberg D E, et al.** Beer binging and mortality: results from the Kuopio Ischaemic Heart Disease Risk factor Study, a prospective population based study. *Br. Med. J.*, 1997; 315, 846-851.
 - **Kautzner J, Yi G, Camm A J, et al.** Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. *Pacing Clin Electrophysiol* 1994; 17:928–37.
 - **Kawachi J, Colditz G A, Stampfer M J, et al.** Smoking cessation in relation to total mortality rates in women. *Ann. Intern. Med.*, 1993; 119,992-1000.
 - **Kleber A G.** Extracellular potassium accumulation in acute myocardial ischemia. *J Mol Cell Cardiol* 1984; 16:389– 394.
 - **Kleinschmidt K, Brady WJ.** Acute coronary syndromes: an evidence-based review and outcome-optimizing guidelines for patients with and without procedural coronary intervention (PCI). Part III: fibrinolytic therapy, procedural coronary

intervention, multi-modal approaches, and medical prophylaxis with low molecular weight heparins. In: Hospital Medicine Consensus Reports. Atlanta, GA: American Health Consultants, 2001.

- **Kontny F.** Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. *Am J Cardiol* 1997; 80: 55E–60E.
- **Kors JA, van Herpen G, van Bommel J H.** QT dispersion as an attribute of T-loop morphology. *Circulation*. 1999; 99:1458–1463.
- **Kosmala W, Przewlocka-Kosmala M, Halawa B.** QT dispersion and myocardial viability in patients after acute myocardial infarction. *Int J Cardiol* 2004; 94:249–54.
- **Kristensen S D, Ravn H B, Falk E.** Insights into the pathophysiology of unstable coronary artery disease. *Am J Cardiol* 1997; 80:5E–9E.
- **Kuo C-S, Munakata K, Reddy P, et al.** Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. *Circulation*. 1983; 67:1356–1367.
- **Kuvin J T, Kimmelstiel C D.** Infectious causes of atherosclerosis. *Am. Heart J.*, 1999; 137, 216-226.
- **Kyriakides Z S, Markianos M, Michalis L.** Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. *Clin Cardiol* 2000; 23:285-288.

-
- **Laakso M, Aberg A, Savola J, et al.** Diseases and drugs causing prolongation of the QT interval. *Am J Cardiol* 1987; 59:862-5.
 - **Laasko M.** Insulin resistance and coronary heart disease. *Curr. Opin. Lipidol*, 1996; 7, 217-226.
 - **Lai C C, Hsiao H C, Hsiao S H, et al.** Role of Shortened QTc Dispersion in In-hospital Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome *J Chin Med Assoc* 2006; 69(7): 297–303.
 - **LaRosa J C.** Triglycerides and coronary risk in women and the elderly. *Arch Intern Med*, 1997; 157,961-968.
 - **Laszio M, Andras K.** Effect of fluvastatin on QT dispersion: A New Pleiotropic Effect. *Am. J. Cardiol.* 2002, 15: 919-920.
 - **Lau CP, Freedman AR, Fleming S, et al.** Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. *Cardiovasc Res.* 1987; 22:67–72.
 - **Law M R, Morris J K, Wald N J.** Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. *Br. Med. J.*, 1997; 315, 973-982.
 - **Lee T M, Su S F, Wang T D, et al.** Increased ventricular repolarization inhomogeneity during postural changes in patients with syndrome X. *Am J Cardiol* 1998; 82:615–620.
 - **Leebeek F W G, Boersma E, Cannon C P, et al.** Oral glycoprotein IIb/IIIareceptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. *Eur Heart J* 2002; 23: 444–57.
 - **Lepeschkin E, Surawicz B.** Measurement of the QT interval of the electrocardiogram. *Circulation* 1952; 6:378–388.

-
- **Levitt M A, Promes S B, Bullock S, et al.** Combined cardiac marker approach with adjunct two-dimensional echocardiography to diagnose acute myocardial infarction in the emergency department. *Ann, Em. Med.*, 1996; 27: 1-7.
 - **Levy D, Anderson K M, Savage D D, et al.** Echocardiographically detected left ventricular hypertrophy prevalence and risk factors. The Framingham Heart Study. *Ann. Intern. Med.*, 1988; 108, 7-13.
 - **Li Z, Vincent G M.** Sympathetic modulation affects repolarisation disparity in long QT syndrome and normals: QTp/Qte changes during exercise and beta-blockade. *J Am Coll Cardiol* 1994; (Feb Special Issue) 37A.
 - **Libby P. Inflammation in atherosclerosis.** *Nature.* 2002; 420 (6917): 868-874.
 - **Lionel H O, Bernard J G.** *Drugs for the heart.* 6th ed. Philadelphia, Elsevier: 2005, 353 – 354.
 - **Liuzzo G, Biasucci L M, Galimore R, et al.** The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. *N. Engl. J. Med.*, 1994; 331, 417-424.
 - **Lowe M D, Rowland E, Grace A A.** QT dispersion and triple vessel coronary disease. *Lancet* 1997; 349: 1174–6.
 - **Lyras T G, Papapanagiotou V A, Foukarakis M G, et al.** Evaluation of Serial QT Dispersion in Patients with First Non-Q-Wave Myocardial Infarction: Relation to the Severity of Underlying Coronary Artery Disease. *Clin. Cardiol.* 2003 26, 189–195.

-
- **Macfarlane P W, Lawrie TDV.** Comprehensive electrocardiology: theory and practice in health and disease. New York, Pergamon Press, 1989 3, 1785.
 - **Macfarlane P W, Lawrie TDV.** The normal electrocardiogram and vectrocardiogram. In: Macfarlane PW, Lawrie TDV, eds. Comprehensive Electrocardiology. Oxford, Pergamon, 1989:407–57.
 - **Macfarlane P W, McLaughlin S C, Rodger J C.** Influence of lead selection and population on automated measurement of QT dispersion. *Circulation*1998; 98:2160–7.
 - **Mahaffey K W, Granger C B, Collins R, et al.** Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. *Am J Cardiol* 1996; 77:551-6.
 - **Malarvili M B, Hussain S, Ab-Rahim et al.** Development of Automated 12-Lead QT Dispersion Algorithm for Sudden Cardiac Death. *The Internet Journal of Medical Technology*. 2005. 2 (2).
 - **Malik M, Bradford A.** Human precision of operating a digitizing board: implications for electrocardiogram measurement. *PACE*. 1998; 21:1656–1662.
 - **Malik M, Camm A J.** Mystery of QTc interval dispersion. *Am J Cardiol*1997; 79:785–7.
 - **Malinow M R, Duell P B, Hess D L, et al.** Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N. Engl. J. Med.*, 1998; 338, 1009-1015.

-
- **Manninen V, Tenkanen H, Koskinen P, et al.** Joint effects of serum triglycerides and LDL cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart disease Study. Implications for treatment. *Circulation*, 1992; 85, 37-45.
 - **Manttari M, Oikarinen L, Manninen V, et al.** QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. *Heart* 1997; 78:268–272.
 - **Mantymaa P, Vuolteenaho O, Marttila M.** Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. *Endocrinology* 1993; 133:1470.
 - **Marino P L.** The ICU Book, 3rd Edition. Lippincott Williams & Wilkins. 2007: 318.
 - **Mayet J, Shahi M, McGrath K, et al.** Left ventricular hypertrophy and QT dispersion in hypertension. *Hypertension* 1999, 28: 791-796.
 - **McAlister F A, Teo K K.** Antiarrhythmic therapies for the prevention of sudden cardiac death. *Drugs* 1997; 54:235—52.
 - **McCarthy B D, Beshansky J R, D'Agostino R B, et al.** Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. *Ann Emerg Med*. 1993; 22:579-582.
 - **McCarthy B D, Wong J B, Selker H P.** Detecting acute cardiac ischemia in the emergency department: a review of the literature. *J Gen Intern Med* 1990; 5:365-73.

-
- **McLaughlin N B, Campbell R W F, Murray A.** Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram. *Br Heart J* 1995; 74:84–9.
 - **McLaurin M D, Apple F S, Voss EM, et al.** Serum cardiac troponin I, cardiac troponin T, and CK MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. *Clin Chem* 1997; 43:976-82.
 - **McMahon, R., Peto, R., Cuttler, G. et al.** Blood pressure, stroke and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*, 1990; 335, 765-774.
 - **McNamara R L, Herrin J, Bradley E H.** Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. *J Am Coll Cardiol*: 47, 2006; 45-51.
 - **McTavish D, Faulds D, Goa K L.** Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. *Drugs* 1990;40(2):239-59.
 - **Mehta N J, Khan I A, Mehta R N, et al.** Effect of thrombolytic therapy on QT dispersion in elderly versus younger patients with acute myocardial infarction. *Am J Ther* 2003; 10:7–11.
 - **Moliterno D J, Jokinen E V, Miserez A R, et al.** No association between plasma lipoprotein (a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. *Arterioscler. Thromb. Vasc. Biol.*, 1996; 16, 1568-1572.
 - **Montalescot G, Borentain M, Payot L, et al.** Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary

percutaneous coronary intervention of acute STsegment elevation myocardial infarction: a meta-analysis. *JAMA* 2004; 292:362—6.

- **Morrison L J, Verbeek P R, McDonald A C, et al.** Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. *JAMA* 2000; 283:2686—92.
- **Morrow D A, de Lemos J A, Sabatine M S.** Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. *J Am Coll Cardiol* 2003; 41:1264-1272.
- **Moss A J, Zareba W, Benhorin J, et al.** ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarisation: task force summary. *Ann Noninvasive Electrocardiol* 2001, 6(4):333-41.
- **Mukherjee D, Fang J, Chetcuti S, et al.** Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes. *Circulation*. 2004; 109:745-749.
- **Mulay D V, Quadri S M.** QT dispersion and early arrhythmic risk in acute myocardial infarction. *Indian Heart J* 2004; 56:634—41.
- **Murray A, McLaughlin N B, Bourke J P, et al.** Errors in manual measurement of QT intervals. *Br Heart J* 1994; 71:386—90.
- **Naas AA, Davidson NC, Thompson C, et al.** QT and QTc dispersion are accurate predictors of cardiac death in newly

diagnosed non-insulin dependent diabetes: cohort study. *Br Med J* 1998; 316:745–6.

- **Nallamothu B K, Bates E R, Herrin J, et al.** Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NORMI)-3/4 analysis. *Circulation*: 111, 2005; 761-767.
- **Nathan D M, Meigs J, Singer D E.** The epidemiology of cardiovascular disease in Type 2 diabetes mellitus: how sweet it is ... or is it? *Lancet*, 1997; 350, 4-9.
- **Neaton J D, Blackburn H, Jacobs D, et al.** Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. *Arch. Intern. Med.*, 1992; 152, 1490-1500.
- **O'Doherty M, Tayler D I, Quinn E, et al.** Five hundred patients with myocardial infarction monitored within one hour of symptoms. *BMJ* 1983; 286:1405—8.
- **Omenn G S, Goodman G E, Thronquist M D, et al.** Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. *J. Natl. Cancer Inst.*, 1996; 88,1550-1559.
- **Organisation to Assess Strategies for Ischemic Syndromes II Investigators.** Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina and revascularisation procedures in patients with acute myocardial ischemia without ST segment elevation: a randomised trial. *Lancet* 1999; 353:429-38.

-
- **Organisation to Assess Strategies for Ischemic Syndromes Investigators.** Comparison of the effects of two doses of recombinant hirudin with heparin in patients with acute myocardial infarction without ST segment elevation. *Circulation* 1997; 96:769-77.
 - **Ozdemir K, Altunkeser B B, Aydin M, et al.** New parameters in the interpretation of exercise testing in women: QTc dispersion and QT dispersion ratio difference. *Clin Cardiol* 2002; 25:187–192.
 - **Papadakis J A, Ganotakis E S, Jagroop I A, et al.** Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. *Am. J.Hypertens.*, 1999; 12, 673-681.
 - **Papadakis J A, Ganotakis E S, Mikhailidis D P, et al,** Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality? *J.Roy. Soc. Health* 2000 (in press).
 - **Parale G P, Adnaik A R, Kulkarni P M.** Dynamics of QT dispersion in acute myocardial infarction. *Indian Heart J* 2003; 55: 628–31.
 - **Paffenbarger R S Jr, Hyde R T, Wing A L, et al.** The association of changes in physical activity level and other lifestyle characteristics with mortality among men. *N. Engl. J. Med.*, 1993 328, 538-545.
 - **Parodi O, Simonetti I, Michelassi C.** Comparison of verapamil and propranolol therapy for angina pectoris at rest. A randomized, multiple crossover, controlled trial in the coronary care unit. *Am J Cardiol* 1986; 57: 899 – 906.

-
- **Paventi S, Bevilacqua U, Parafati M A, et al.** QT dispersion and early arrhythmic risk during acute myocardial infarction. *Angiology* 1999; 50: 209 –15.
 - **Pekdemir M, Karaca I, Cevik Y, et al.** The diagnostic value of QT dispersion for acute coronary syndrome in patients presenting with chest pain and non diagnostic initial electrocardiograms. *Mt Sinai J Med.* 2006; 73(5):813-7
 - **Perkiomaki J S, Ikaheimo M J, Pikkujamsa S M, et al.** Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. *Hypertension* 1996, 28: 16-21.
 - **Petersen J L, Mahaffey K W, Hasselblad V, et al.** Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. *JAMA* 2004; 292:89—96.
 - **Pollack C V, Cohen M.** Outcome-effective management of acute coronary syndromes: guidelines, protocols, and recommendations for emergency medicine practice. 2002: American Health Consultants; In: CEVAT Panel Reports. Atlanta, GA.
 - **Pollack CV, Gibler WB.** 2000 ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a practical summary for emergency physicians [published corrections appear in *Ann Emerg Med* 2001; 38: 468 and *Ann Emerg Med* 2002; 39 : 100]. *Ann Emerg Med* 2001; 38: 229-40.

-
- **Pope J H, Aufderheide T P, Ruthazer R, et al.** Missed diagnoses of acute cardiac ischemia in the emergency department. *N Engl J Med.* 2000; 342:1163-1170.
 - **Pope J H, Selker H P.** Diagnosis of acute cardiac ischemia. *Emerg Med Clin North Am* 2003; 21:27-59.
 - **Prescott E, Hippe M, Schnohr P, et al.** Smoking and the risk of myocardial infarction in women and men: longitudinal population study. *Br. Med. J.*, 1998; 316, 1043-1047.
 - **Psallas M, Tentolouris N, Cokkinos A, et al.** QT dispersion: comparison between diabetic and non-diabetic individuals and correlation with cardiac autonomic neuropathy. *Hellenic J Cardiol.* 2006; 47(5):255-62.
 - **Puddu P E, Bourassa M G.** Prediction of sudden death from QTc interval prolongation in patients with chronic ischemic heart disease. *J Electrocardiol* 1986; 19: 203-12.
 - **Puljevic D, Smalcelj A, Durakovic Z, et al.** Effects of postmyocardial infarction scar size, cardiac function, and severity of coronary artery disease on QT interval dispersion as a risk factor for complex ventricular arrhythmia. *PACE* 1998; 21:1508 –1516.
 - **Rajagopal V, Bhatt D L.** Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. *Semin Thromb Hemost.* 2004; 30(6): 649-655.
 - **Rajavashisth T B, Liao J K, Galis Z S, et al.** Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. *J Biol Chem.* 1999; 274(17):11924-11929.

-
- **Ramos M A, Kuzuya M, Esaki T, et al.** Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. *Arterioscler Thromb Vasc Biol.* 1998; 18(7):1188-1196.
 - **Rana B S, Band M M, Ogston S, et al.** Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. *Am. J. Cardiol.* 2002, 90: 483-487.
 - **Rautaharju PM.** QT and dispersion of ventricular repolarization: the greatest fallacy in electrocardiography in the 1990s. *Circulation* 1999; 99:2477–8.
 - **Rawles J M, Kenmure A C.** Controlled trial of oxygen in uncomplicated myocardial infarction. *BMJ* 1976; 1:1121—3.
 - **Ribichini F, Ferrero V, Wijns W.** Reperfusion treatment of ST-elevation acute myocardial infarction. *Prog Cardiovasc Dis:* 47, 2004; 131-157.
 - **Ridker P M.** Evaluating novel cardiovascular risk factors: can we better predict heart attacks? *Ann.Intern. Med.*, 1999; 130, 933-937.
 - **Rimm B, Stampfer M J, Giovannucci E et al.** Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. *Am. J. Epidemiol.*, 1995; 141, 1117-1127.
 - **Robillon J F, Sadoul J L, Benmerabet S, et al.** Assessment of cardiac arrhythmic risk in diabetic patients using QT dispersion abnormalities. *Diabetes Metab.* 1999, 25: 419-423.
 - **Roffi M, Chew D P, Mukherjee D et al.** Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-

ST-segment-elevation acute coronary syndromes. *Circulation* 2001; 104: 2767–71.

- **Ross R.** Atherosclerosis, an inflammatory disease. *N Engl J Med* 1999; 340(2):115-26.
- **Sacks F M, Pfeffer M A, Moye L, et al.** The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N. Engl. J. Med.*, 1996; 335, 1001-1009.
- **Sadowski Z P, Alexander J H, Skrabucha B, et al.** Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. *Am Heart J* 1999; 137:792— 8.
- **Sahu P, Lim P O, Rana B S, et al.** QT dispersion in medicine: electrophysiological Holy Grail or fool's gold? *Q J Med* 2000; 93: 425-431.
- **Sarma J S, Sarma R J, Bilitch M, et al.** An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. *Am J Cardiol* 1984; 54:103–8.
- **Savage D D, Garrison R J, Kannel W B, et al.** The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. *Circulation*, 1987; 75, 126-133.
- **Savonitto S, Ardissino D, Granger C B, et al.** Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999; 281: 707–713.
- **Schaefer E J, Lamon-Fava S, Jenner J L, et al.** Lipoprotein (a) levels and risk of coronary heart disease in men. *The Lipid*

Research Clinics Coronary Primary Prevention Trial. JAMA, 1994; 271, 999-1003.

- **Schmidt M, Schneider C, Theissen P, et al.** QT dispersion in comparison to Tl-201-SPECT for detection of myocardial ischaemia. Int J Cardiol. 2006; 113(3):327-31.
- **Schneider C A, Voth E, Baer F M, et al.** QT dispersion is determined by the extent of viable myocardium in patients with chronic Q-wave myocardial infarction. Circulation 1997; 96:3913–20.
- **Schrör K.** Antiplatelet drugs: a comparative review. Drugs 1995; 50(1):7-28.
- **Schwarz M, Nordt T, Bode C, et al.** The GPIIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, α 5 β 2). Thromb Res 2002; 107:121–128.
- **Scirica BN, Morrow BA.** Troponins in acute coronary syndromes. Semin Vasc Med 2003; 3:363-74.
- **Sredniawa B, Musialik-Lydk A, Jarski P, et al.** Methods of Assessment and Clinical Relevance of QT Dynamics. Indian Pacing and Electrophysiology Journal 2005, 5(3): 221-232.
- **Serruys PW, Herrman J R, Simon R, et al.** A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333:757-63.
- **Shah C P, Thakur R K, Reisdorff E J, et al.** QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center. Am Heart J 1998; 136: 496–8.
- **Shaper A G, Wannamethee S G, Walker M.** Body weight: implications for the prevention of coronary heart disease, stroke,

and diabetes mellitus in a cohort study of middle-aged men.

Br.Med. J., 1997; 314, 1311-1317.

- **Sharis P J, Cannon C P, Loscalzo J.** The antiplatelet effects of ticlopidine and clopidogrel. *Ann Intern Med* 1998;129:394-405
- **Shepherd J, Cobbe S M, Ford I, et al.** Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N. Engl. J. Med.*, 1995; 333, 1301-1307.
- **Silva D P, Landt Y, Porter S E, et al.** Development and application of monoclonal antibodies to human cardiac myoglobin in a rapid fluorescence immunoassay. *Clin Chem.* 1991; 37:1356–1364.
- **Simoons M L.** Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* 2001; 357:1915—24.
- **Singh K.** Effect of smoking on QT interval, QT dispersion and rate pressure product. *Indian Heart J.* 2004; 56(2):140-2.
- **Sirinivas V S, Cannon C P, Gibson C M, et al.** Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. *Am Heart J* 2001; 142:29-36.
- **Somberg J C, Molnar J.** Usefulness of QT dispersion as an electrocardiographically derived index. *Am J Cardiol* 2002; 89:291–294.
- **Spargias K S, Lindsay S J, Kwar G I, et al.** QT dispersion is a predictor of long-term mortality in patients with acute

myocardial infarction and clinical evidence of heart failure. *Eur Heart J* 1999; 20:1158–65.

- **Sporton S C, Taggart P, Sutton P M, et al.** Acute ischaemia: a dynamic influence on QT dispersion. *Lancet* 1997; 349: 306–9.
- **Sredniawa B, Musialik-ydka A, Pasyk S, et al.** Dispersion of the QT interval in unstable angina pectoris. *Pol Arch Med Wewn.* 2000; 103(1-2):41-5.
- **Stampfer M J, Malinow M R, Willett W C, et al.** A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. *JAMA*, 1992; 268, 877-881.
- **Statters D J, Malik M, Ward D E, et al.** QT dispersion: problems of methodology and clinical significance. *J Cardiovasc Electrophysiol* 1994; 5:672–85.
- **Steg P G, Bonnefoy E, Chabaud S.** Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation*: 108, 2003; 2851-2856.
- **Stein J H, Rosensons R S.** Lipoprotein Lp(a) excess and coronary heart disease. *Arch. Intern.Med.*, 1997; 157, 1170-1176.
- **Steinhubl S R, Berger P B, Tift Mann J III, et al.** Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; 288:2411–2420.
- **Steinhuble S R, Tan W A, Foody J M, et al.** Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. *EPISTENT*

investigators. Evaluation of platelet IIb-IIIa inhibitor for stenting. *JAMA* 1999; 281:806-10.

- **Stephens S G, Parsons A, Schofield P M, et al.** Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet*, 1996; 347, 781-786.
- **Stone G W, Grines C L, Rothbaum D.** PAMI Trial Investigators. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. *J Am Coll Cardiol*: 29, 1997; 901-907.
- **Stukel T A, Lucas F L, Wennberg D E.** Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare patients with acute myocardial infarction. *JAMA* 2005; 293(11):1329-37.
- **Suh I, Shaten J B, Cutler J A, et al.** Alcohol use and mortality from coronary heart disease: The role of high-density lipoprotein cholesterol. *Ann. Intern. Med.*, 1992, 116, 881.
- **Surawicz B.** Will QT dispersion play a role in clinical decision-making? *J Cardiovasc Electrophysiol*. 1996; 7:777–784.
- **Suzuki M, Nishizaki M, Arita M, et al.** Increased QT dispersion in patients with vasospastic angina. *Circulation* 1998; 98:435–440.
- **Swedberg K, Held P, Kjeksus J, et al.** Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med* 1992; 327:678—84.

-
- **Tamer A, Arinc H, Gunduz H, et al.** The Effect of Coronary Risk Factors on QT Dispersion. *The Cardiol.* 2005; 1 (3-4): 189-193.
 - **Tamura A, Nagase K, Mikuriya Y, et al.** Relation of QT dispersion to infarct size and left ventricular wall motion in anterior wall acute myocardial infarction. *Am J Cardiol* 1999; 83:1423–1426.
 - **Teo K K, Yusuf S, Pfeffer M, et al.** Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. *Lancet* 2002; 360:1037—43.
 - **The MIAMI Trial Research Group.** Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. *Eur Heart J* 1985; 6:199—226.
 - **Theroux P, Fuster V.** Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. *Circulation* 1998; 97: 1195–206.
 - **Theroux P, Ouimet H, McCans J, et al.** Aspirin, heparin, or both to treat acute unstable angina. *N Engl J Med* 1988; 319:1105-1111.
 - **Theroux P, Taeymans Y, Morissette D et al.** A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. *J Am Coll Cardiol* 1985; 5: 717–22.
 - **Thom T, Haase N, Rosamond W, et al.** Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation.* 2006; 113(6):85-151.

-
- **Tikiz H, Terzi T, Balbay Y, et al.** QT dispersion in single coronary artery disease: is there a relation between QT dispersion and diseased coronary artery or lesion localization? *Angiology*. 2001; 52(1): 43-51.
 - **Toschi V, Gallo R, Lettino M, et al.** Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation*. 1997; 95(3): 594-599.
 - **Trichopoulou A, Kouris-Blazos A, Wahlqvist M L, et al.** Diet and overall survival in elderly people. *Br. Med. J.*, 1995; 311, 1457-1460.
 - **van de Loo A, Arendts W, Hohnloser S H.** Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. *Am J Cardiol* 1994; 74:1113–18.
 - **Van de Werf F J, Armstrong P W, Granger C, et al.** Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT- 3 randomised trial in acute myocardial infarction. *Lancet* 2001; 358:605—13.
 - **van Domburg R T, van Miltenburg-van Zijl A J, Veerhoek R J, et al.** Unstable angina: good long-term outcome after a complicated early course. *J Am Coll Cardiol* 1998; 31: 1534–9.
 - **Van Kooten F, van Krimpen J, Dippel D W, et al.** Lipoprotein (a) in patients with acute cerebral ischemia. *Stroke*, 1996; 27, 1231-1235.
 - **Van't Hof A W, Ernst N, de Boer M J, et al.** Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial

infarction evaluation (On-TIME) trial. *Eur Heart J* 2004; 25:837—46.

- **Varo N, de Lemos J A, Libby P, et al.** Soluble CD40L: risk prediction after acute coronary syndromes. *Circulation* 2003; 108: 1049 –1052.
- **Vaughan D E.** Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. *Circulation*. 2003; 108(4): 376-377.
- **Veglio M, Bruno G, Borra M, et al.** Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: A population-based cohort. *J. Intern. Med.* 2002, 251: 317-324.
- **Verduyn S C, Vos M A, Zande J, et al.** Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired Torsade de Pointes arrhythmias. *J Am Coll Cardiol* 1997; 30:1575–1584.
- **Viskin S.** Long QT syndromes and torsades de pointes. *Lancet* 1999; 354:1625-33.
- **Wagner G S, Marriott H J.** Marriott's Practical electrocardiography. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:165.
- **Wallentin L, Goldstein P, Armstrong P W, et al.** Efficacy and safety of tenecteplase in combination with the lowmolecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. *Circulation* 2003; 108:135—42.

-
- **Waller A D.** A demonstration on man of electromotive changes accompanying the heart's beat. *J Physics* 1887; 8:229.
 - **Wannamethee S G, Shaper A G, Walker M.** Changes in physical activity mortality, and incidence of coronary heart disease in older men. *Lancet*, 1998; 351, 1603-1608.
 - **Waters D D.** Diagnosis and management of patients with unstable angina. In: Fuster V, Alexander RW, O'Rourke, RA, et al, eds. *Hurst's the Heart*, 10th ed. New York: McGraw-Hill; 2001:1237–1274.
 - **Welsh R C, Goldstein P, Adgey J, et al.** Variations in prehospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. *Eur J Emerg Med* 2004; 11:134—40.
 - **White H D, Aylward P E, Frey M J, et al.** Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). *Circulation* 1997; 96:2155-61.
 - **Wilde A A.** Role of ATP-sensitive K⁺ channel current in ischemic arrhythmias. *Cardiovasc Drugs Ther* 1993; 7:521– 526.
 - **Wilking S V B, Belanger A. J., Kannel W B, et al.** Determinants of isolated systolic hypertension. *JAMA*, 1988; 260, 3451.
 - **Wilson F N, MacLeod A G, Parker P S, et al.** Determination of the significance of the areas of ventricular deflections of the electrocardiogram. *Am Heart J* 1934; 10:46–61.
 - **Wood D, Backer G D, Faergeman O, et al.** together with members of the Task Force. Prevention of coronary heart disease

in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. *Atherosclerosis*, 1998; 140, 199-270.

- **Yang Z, Zhang W, Liu Y.** Prognostic efficacy of Troponin T measurement in angina pectoris. *Chin. Med. J. (Engl)*, 1995; 108: 626-630.
- **Yano K, Reed D M, McGee D L.** Ten year incidence of coronary heart disease in the Honolulu Heart Program: relationship to biological and lifestyle characteristics. *Am. J. Epidemiol.*, 1984; 119,653-666.
- **Yao S K, McNatt J, Cui K, et al.** Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium injured arteries in nonhuman primates. *Circulation* 1993; 88(6):2888-93.
- **Yap Y G, Yi G, Guo X-H, et al.** Dynamic changes of QT dispersion and its relationship with clinical variables and arrhythmic events after myocardial infarction (abstr). *J Am Coll Cardiol* 1999; 33 Suppl A: 107A.
- **Yilmaz R, Demirbag R, and Gur M.** The Association of QT Dispersion and QT Dispersion Ratio with Extent and Severity of Coronary Artery Disease A.N.E. 2006; 11(1):43–51.
- **Yunus A, Gillis AM, Traboulsi M, et al.** Effect of coronary angioplasty on precordial QT dispersion. *Am J Cardiol* 1997; 79:1339–1342.
- **Zabel M, Portnoy S, Franz M R.** Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. *J Am Coll Cardiol*. 1995; 25:746–752.

-
- **Zabel M, Wolfgang J.** Rate dependence of the QT interval and of QT dispersion: comparison of atrial pacing and exercise testing. *Circulation* 1997; 96(Suppl I):1–325.
 - **Zavaroni I, Bonora E, Pagliara M, et al.** Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. *N. Engl. J. Med.*, 1989; 320, 703-706.
 - **Zimetbaum P J, Josephson M E.** Use of the electrocardiogram in acute myocardial infarction. *N Engl J Med* 2003; 348:933-40.